Metastatic Disease Clinical Trials

1 recruiting

Metastatic Disease Trials at a Glance

42 actively recruiting trials for metastatic disease are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 20 trials, with the heaviest enrollment activity in Toronto, Los Angeles, and Beijing. Lead sponsors running metastatic disease studies include University Health Network, Toronto, National Medical Research Radiological Centre of the Ministry of Health of Russia, and Fudan University.

Browse metastatic disease trials by phase

Treatments under study

About Metastatic Disease Clinical Trials

Looking for clinical trials for Metastatic Disease? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 42 trials

Recruiting

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Prostate CancerAdvanced Prostate CancerProstate Cancer Metastatic Disease+1 more
Maastricht Radiation Oncology600 enrolled3 locationsNCT07004582
Recruiting
Phase 2

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression

Ovarian CancerOligometastatic DiseaseSerous Ovarian Tumor
MedSIR30 enrolled14 locationsNCT06180356
Recruiting
Phase 2

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Prostate Cancer Metastatic Disease
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine192 enrolled1 locationNCT06832774
Recruiting
Phase 1Phase 2

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC)Unresectable Locally Advanced or Metastatic Disease
Beijing Biotech42 enrolled1 locationNCT07480928
Recruiting
Not Applicable

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Quality of LifeOligometastatic DiseaseToxicity Due to Radiotherapy+1 more
Robert Olson598 enrolled13 locationsNCT05784428
Recruiting
Phase 2

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Prostate CancerProstate CarcinomaProstate Neoplasm+12 more
Shehzad Basaria, M.D.60 enrolled1 locationNCT06957691
Recruiting
Not Applicable

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

Metastatic MelanomaOligoProgressive Metastatic Disease
University Health Network, Toronto52 enrolled1 locationNCT07112170
Recruiting
Phase 2

Using FAPI PET/MRI to Evaluate Prostate Cancer

Prostate CancersProstate Cancer Metastatic Disease
University of Wisconsin, Madison30 enrolled1 locationNCT06675357
Recruiting
Phase 1

Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)

Oligometastatic DiseaseOligometastasis
Case Comprehensive Cancer Center15 enrolled1 locationNCT07079098
Recruiting
Phase 2

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

Prostate Cancer SurgeryProstate Cancer Metastatic Disease
Clinton Bahler22 enrolled3 locationsNCT06849544
Recruiting
Not Applicable

PSMA PET for Surveillance After Focal Therapy

Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic DiseaseProstate Cancer (Diagnosis)
University of Chicago62 enrolled1 locationNCT07115914
Recruiting
Not Applicable

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

OligoProgressive Metastatic Disease
Jules Bordet Institute48 enrolled5 locationsNCT06925984
Recruiting
Early Phase 1

Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography

Oligometastatic Disease
Katelyn Atkins10 enrolled1 locationNCT06373497
Recruiting

Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer

Prostate Cancer Metastatic Disease
University Hospital, Grenoble130 enrolled1 locationNCT06828263
Recruiting
Not Applicable

Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers

Oligometastatic DiseaseOligoProgressive Metastatic DiseaseOligoprogression
British Columbia Cancer Agency194 enrolled1 locationNCT06918951
Recruiting
Not Applicable

Role of Race in Nutritional Approach in Men on ADT

Prostate Cancer Metastatic Disease
University of California, Los Angeles70 enrolled2 locationsNCT06682390
Recruiting
Not Applicable

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)

Radiotherapy Side EffectProstate CancerOligometastatic Disease+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT05183074
Recruiting
Phase 1Phase 2

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

Solid Tumor, AdultOligometastatic Disease
Gustave Roussy, Cancer Campus, Grand Paris58 enrolled2 locationsNCT06439888
Recruiting
Phase 2Phase 3

A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)

OligoProgressive Metastatic Disease
M.D. Anderson Cancer Center400 enrolled1 locationNCT06367972
Recruiting
Phase 2

TERPS Trial for de Novo Oligometastic Prostate Cancer

Prostate CancerOligometastatic Disease
University of Maryland, Baltimore122 enrolled9 locationsNCT05223803